Provided by Tiger Trade Technology Pte. Ltd.

BioNTech SE

93.07
-2.1800-2.29%
Volume:161.68K
Turnover:15.10M
Market Cap:23.38B
PE:-11.97
High:94.45
Open:93.81
Low:92.81
Close:95.25
52wk High:124.00
52wk Low:79.52
Shares:251.20M
Float Shares:109.00M
Volume Ratio:1.60
T/O Rate:0.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.7726
EPS(LYR):-5.5184
ROE:-9.30%
ROA:-5.41%
PB:1.18
PE(LYR):-16.87

Loading ...

BioNTech Names KPMG as New Independent Auditor for 2027 Financial Year

TIPRANKS
·
Sep 19

BioNTech Names KPMG as Independent Auditor for Fy2027

Reuters
·
Sep 19

Top Pharvaris Executive Cashes In on Major Insider Stock Sale

TIPRANKS
·
Sep 18

Sector Update: Healthcare

MT Newswires Live
·
Sep 18

Health Canada Authorizes Pfizer-BioNTech XFG-Adapted COVID-19 Vaccine

Reuters
·
Sep 18

Shionogi’s Phase 3 COVID-19 Antiviral Trial Puts SGIOF Back in the Spotlight

TIPRANKS
·
Sep 18

BioNTech CEO Uğur Şahin Sells $4.73 Million in Common Shares

Reuters
·
Sep 17

BioNTech price target raised to $140 from $132 at Berenberg

TIPRANKS
·
Sep 16

Berenberg Bank Reaffirms Their Buy Rating on BioNTech SE (BNTX)

TIPRANKS
·
Sep 16

Jefferies Remains a Buy on BioNTech SE (BNTX)

TIPRANKS
·
Sep 16

European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading

MT Newswires Live
·
Sep 15

Analysts Offer Insights on Healthcare Companies: Benitec Biopharma (BNTC), CVS Health (CVS) and BioNTech SE (BNTX)

TIPRANKS
·
Sep 15

BioNTech and OncoC4 Report Survival Gains for Gotistobart in Phase 3 Squamous NSCLC Trial

TIPRANKS
·
Sep 14

BioNTech SE (BNTX) Gets a Buy from Morgan Stanley

TIPRANKS
·
Sep 14

BioNTech Says Lung Cancer Drug Candidate Prolonged Lives in Trial

Reuters
·
Sep 14

Movement Alert|BioNTech SE Rises 5.04% in Pre-Market Trading, Phase 3 Lung Cancer Trial Shows Statistically Significant Survival Benefit

Market Focus
·
Sep 14

BioNTech's Lung Cancer Drug Nearly Doubles Survival in Late-Stage Trial, Boosting Oncology Pivot

Stock News
·
Sep 14

BioNTech, OncoC4 announce first median overall survival data from PRESERVE-003

TIPRANKS
·
Sep 14

BioNTech, OncoC4 Report Positive Overall Survival Data From Phase 3 Trial of Gotistobart in Lung Cancer

MT Newswires Live
·
Sep 14

BioNTech CEO Uğur Şahin Sells 20,500 Shares for $1.97 Million

Reuters
·
Sep 12